Send to

Choose Destination
Future Med Chem. 2017 Jul;9(11):1227-1242. doi: 10.4155/fmc-2017-0068. Epub 2017 Jul 19.

Advances toward LSD1 inhibitors for cancer therapy.

Author information

College of Public Heath, Zhengzhou University, Zhengzhou 450001, China.
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
School of Pharmaceutical Sciences & Collaborative Innovation Center of New Drug Research & Safety Evaluation, Zhengzhou University, Zhengzhou 450001, China.


LSD1 has become an important biologically validated epigenetic target for cancer therapy since its identification in 2004. LSD1 mediates many cellular signaling pathways and is involved in the initiation and development of cancers. Aberrant overexpression of LSD1 has been observed in different types of cancers, and inactivation by small molecules suppresses cancer cell differentiation, proliferation, invasion and migration. To date, a large number of LSD1 inhibitors have been reported, RG6016, GSK-2879552, INCB059872, IMG-7289 and CC-90011 are currently undergoing clinical assessment for the treatment of acute myeloid leukemia, small-cell lung cancer, etc. In this review, we briefly highlight recent advances of LSD1 inhibitors mainly covering the literatures from 2015 to 2017 and tentatively propose our perspectives on the design of new LSD1 inhibitors for cancer therapy.


LSD1 inhibitors; cancer therapy; tranylcypromine

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center